✦ LIBER ✦

Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase

✍ Scribed by Hu, Bei; Savani, Bipin N.

Book ID: 121751030
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 187 KB
Volume: 93
Category: Article
ISSN: 0902-4441
DOI: 10.1111/ejh.12356

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Front-Line Therapy With Second-Generatio

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

✍ Jabbour, E.; Kantarjian, H. M.; O'Brien, S.; Shan, J.; Quintas-Cardama, A.; Garc 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 126 KB

Towards a need to a “biological Sokal ri

Towards a need to a “biological Sokal risk” in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia

✍ Fabio Stagno; Paolo Vigneri; Francesco Di Raimondo 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 100 KB

A Critical Review of Trials of First-Lin

A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

✍ Jabbour, Elias; Lipton, Jeffrey H. 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 355 KB

Nilotinib as frontline therapy for patie

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd

✍ Hirohisa Nakamae; Hirohiko Shibayama; Mineo Kurokawa; Tetsuya Fukuda; Chiaki Nak 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 289 KB

Phase III, Randomized, Open-Label Study

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

✍ Cortes, J. E.; Baccarani, M.; Guilhot, F.; Druker, B. J.; Branford, S.; Kim, D.- 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 166 KB

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera